Wed, Aug 27, 2014, 11:43 AM EDT - U.S. Markets close in 4 hrs 17 mins

Recent

% | $
Quotes you view appear here for quick access.

Addus HomeCare Corporation Message Board

racavalli 179 posts  |  Last Activity: 22 hours ago Member since: Jul 31, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • According to Fly On The Wall, Citicorp lowered their target price from $21 to $14 but I can't find anybody who has actually seem the report.

    Sentiment: Strong Buy

  • Reply to

    CFO makes $16k/year...

    by wantonfuey Aug 25, 2014 10:30 AM
    racavalli racavalli Aug 26, 2014 2:07 AM Flag

    he took stock in lieu of salary which tells you what he thinks about the shares

    Sentiment: Strong Buy

  • Reply to

    getting ready to pop

    by bill750 Aug 21, 2014 2:41 PM
    racavalli racavalli Aug 25, 2014 12:04 PM Flag

    Looks like shares are starting the anticipated advance.

  • Reply to

    BioLargo’s AOS Filter will benefit ESV

    by odogett Aug 23, 2014 10:22 PM
    racavalli racavalli Aug 25, 2014 11:05 AM Flag

    this kind of spam will make you a lot of money because the story is quite large and it's real

    Sentiment: Strong Buy

  • Reply to

    BioLargo’s AOS Filter will benefit END

    by landvibe Aug 23, 2014 10:05 PM
    racavalli racavalli Aug 25, 2014 11:02 AM Flag

    Suncor confirms their involvement in Canada with the University of Alberta and BioLargo.

    Sentiment: Strong Buy

  • Reply to

    BioLargo’s AOS Filter will benefit EMES

    by untera.l123 Aug 23, 2014 4:36 PM
    racavalli racavalli Aug 25, 2014 10:59 AM Flag

    BioLargo is working with a consortium of oil companies and the University of Albert in Alberta to solve the wastewater issue. You can call Suncor to confirm their involvement as well as RDS and other large companies.

    The University has already validated that BioLargo's AOS Filter/electro-chemical reactor is a major breakthrough because it decontaminates recalcitrant contaminants such as napthenic acids, 1,4 dioxanes and far more in seconds versus hours compared to the other leading technologies . . . . and it uses only 1/20 of the energy.

    The story is so big that most people don't believe it, but it is true and BioLargo shareholders are bout to strike it rich.

    Sentiment: Strong Buy

  • Reply to

    How many years of delay 1 or 2 years

    by drreddygary Aug 21, 2014 6:11 PM
    racavalli racavalli Aug 25, 2014 12:54 AM Flag

    management DOES NOT know the results of the STEP yet!

    The jury is out and the results could be a disaster and unusable because of the temperature breech . . . or they could be the usual grand slam home run.

    We just don't know yet and neither does the company but I am sure they are prepared for the worst and ready to substitute multiple injection data that is even more compelling than single injection data because it is more effective than ever imagined and it still demonstrates NO ADVERSE SIDE EFFECTS.

    Very likely no delay in BLA filing, FDA approval and commercialization in 2015.

    Place your bets!

    Sentiment: Strong Buy

  • racavalli racavalli Aug 25, 2014 12:49 AM Flag

    Yes, it was so good that the FDA called it "ROBUST" and they rarely are that complimentary.

    And the patients treated with Ampion were not compared to UNTREATED patients . . . they were compared to patients treated with saline injections that offered minimal but some degree of efficacy. This means that the efficacy of a single injection of Ampion was somewhat masked by the slight improvement of saline n the placebo group.

    The multiple injection studies at 4 weeks and 6 weeks were off the charts and presented unrivaled data never before seen. At 6 weeks with injections at baseline, 2weeks and 4 weeks, Ampion efficacy was an astonishing 86% based on reduction of pain and 87% based on increase of activity.

    AND THERE WERE NO ADVERSE SIDE EFFECTS . . . AGAIN

    TO DATE THERE HAVE BEEN NO ADVERSE SIDE EFFECTS PROVING SAFETY THAT MAY BE UNPRECEDENTED.

    A 5 year old could tell you what this means and how powerful the implications are. And that does not even take into account the high probability that Ampion regenerates cartilage. When the cartilage regeneration data comes out, it will be very difficult to put a value on AMPE shares because this will be a major historical medical breakthrough that has enormous implications.

    The 12 week data from the multiple injection study is due in 5 to 6 weeks and will include high resolution MRI's and needle aspirations (biopsies) to provide evidence of cartilage regeneration. Thus will be JUST THE BEGINNING!

    Positive data from just this soon upcoming news release as the potential to rocket shares to unimaginable heights.

    Once again . . . place your bets!

    Sentiment: Strong Buy

  • racavalli racavalli Aug 24, 2014 9:12 PM Flag

    Yes, this was a huge mistake by the CRO that the company could have foreseen. It seems only logical that if something like the step study was so important that management would have created a list of everything that could have gone wrong and monitored it closely as extra insurance and communicated with the CRO to remind them to double and triple check.

    My take is that this single negative event will make the company much stronger because they will never make this same kind of mistake again. I also do not believe the BLA filing of Ampion will be delayed.

    Take a close look at the multiple injection data. True, the starting number was only 7, but statistically, the results are unprecedented. The company is already expanding the patient numbers to hundreds and the multiple injection trials produce such remarkable data IN ONLY A FEW WEEKS AND NOT MONTHS. There is absolutely no issue with safety and ULTRA efficacy can be proven in 4 weeks, 6 weeks, 8 weeks and 12 weeks. I believe the BLA filing date will not be delayed. There is not enough evidence to suggest a delay in filing . . . especially when the COMPANY STILL DOES NOT EVEN HAVE THE STEP RESULTS.

    With the overwhelming data they already have from other trials, it seems only reasonable that the FDA will not require redoing the Step. I think the company will make an announcement in the next day or week or two that will clear up all the uncertainties.

    Frightened shareholders and short sellers will keep selling, but my prediction is that they are all going to be very upset with their decisions when they see the real opportunity.

    Ampion and Optina are both huge winners and Zertane and NCE001 are going to surprise very big.

    Just my opinion.

    Place your bets!!!

    Sentiment: Strong Buy

  • There is NO PROBLEM associated with the drug Ampion or any drug in Ampio's pipeline. This is only a procedural problem where we do not even know the magnitude yet. And that procedural problem has created a huge misperception and heavy selling that is creating an opportunity for the experienced and the knowledgeable.

    Even though shares have tanked, STEP results are not in yet and are still unknown.

    What we do know is that Ampion has performed exceptionally well even in the Spring Study where the FDA called results "ROBUST".

    Since then, we have seen astonishing results from the multiple injection study and that study is expanding to much larger numbers. With safety and efficacy data so strong, and with the need so high, it seems more likely that the FDA will do what they can to expedite so millions of patients suffering from pain and potential costly and high risk surgery can benefit.

    Shareholders and traders are certainly free to act on any decisions they make, but I strongly believe this will turn out to be another amazing buying opportunity.

    The amount of really big news in the short term from multiple events is overwhelming and those investors and traders who buy now or hold will be rewarded very handsomely.

    Judging on the price of shares today, most will disagree with me, but that is the the way it is, and is also what provides the opportunity to make very large returns on investment.

    Ampio has not been diminished in any way. I predict that shareholders will quickly do a 180 and will be cheering and praising management.

    Think carefully before making decisions that you will regret later.

    Sentiment: Strong Buy

  • racavalli racavalli Aug 23, 2014 2:20 PM Flag

    i have over 40 years experience in the markets and the best advice you can get is to follow your intuition and double down. AMPE should be held for at least three years and hopefully they will not be bought out by big pharma but that remains to be seen. I have known this company and their pipeline for over three years and am very close to it.

    MY conclusion and recommendation is to ignore all the time wasting chatter from unknowledgeable commentors and short interests and take advantage of an extraordinary opportunity t buy shares at their lows.

    We should be buying when we are afraid and selling when we are confident. That is a time proven axiom in the markets.

    Sentiment: Strong Buy

  • racavalli racavalli Aug 23, 2014 11:45 AM Flag

    Incorrect! CPR Pharma Services was the CRO used by Ampio for the Phase II trial. CPR Oharma is recognized by the FDa and has been in business for over 25 years. A close check will reveal their record is spotless and their reputation is excellent.

    In 2012, after the results were announced form the PII, I spoke with Dr. Yvonne Lungershausen, the Senior Director of the Ampion PII trial. She said, "This is by far the most successful trial we have run in our entire 25 year history." "There was NOT ONE SINGLE ADVERSE SID EFFECT AND THAT WAS HISTORICAL!" "PATIENTS CAME IN DEPRESSED, LIMPING AND HOBBLING AND AFTER THEIR INJECTION OF AMPION, THEY WERE SKIPPING AND DANCING AND LAUGHING WITH JOY." "WE CULDN'T BELIEVE WHAT WE WERE SEEING BECAUSE EACH TIME WE WOULD EXAMINE THE PATIENTS, THE DATA KEPT GETTING BETTER AND BETTER."

    Those were her EXACT words.

    I spoke with the Dream Team in Anaheim, California yesterday and Michelle told me that they are NOT A CRO AND THAT THEY DID NOT TREAT ALL OF THE PATIENTS AS WAS SUGGESTED IN THE FLY ON THE WALL HIRT ARTICLE YESTERDAY.

    She said the CRO for the PIII trial is PRO MEDICA.

    I hope this clears up a lot of incorrect rumors.

    Sentiment: Strong Buy

  • Erroneous rumors are flying andTraders have overreacted and sent shares plummeting.

    Earlier today, the fly on the wall posted a blog saying that the cro was the dream team and that they were the only site in the step study in question.

    i called the dream team tonight and was told that this is INCORRECT AND MISLEADING INFORMATION. They are very upset with the fly on the wall for misrepresenting the truth.

    I was told that there were multiple sites used in the step study and that the Dream Team is only one of the multiple sites used.

    I was also told that ProMedica is the CRO . . . not the Dream Team.

    There is a great deal of emotion surrounding Ampio's recent complication, but it does not in any way indicate Ampion will not get approved and it also does not mean that the BLA will be delayed.

    Management is being accused of lying and pumping. Those accusations are completely false because management did not find out about the temperature breech until just before their Thursday morning announcement. And the company STILL DOES NOT YET HAVE THE RESULTS.

    Strongly recommend understanding that the short interests are playing this situation like a fine tuned instrument but traders will soon wake up and realize they have been duped.

    Decisions about how to keep the BLA on track will be forthcoming and will catch many traders by surprise. jefferies issued very thoughtless report today based on little to no actual research. i have heard from the company that jefferies has NEVER even visited ampio for a face to face interview . . . EVER! its true that they basically just took their fees for the last round and just ran.

    Expect more thorough report by Citicorp in a couple of weeks. Also expect positive announcements soon.

    Caution . . . shares are likely to surprise to the upside soon.

    Nothing has changed and Ampio's pipeline is still a powerhouse that will amaze.

    Sentiment: Strong Buy

  • Reply to

    stability in diketopiperazines - etc...

    by billwilliams836 Aug 21, 2014 5:00 PM
    racavalli racavalli Aug 21, 2014 10:53 PM Flag

    They do not have the data yet!

  • I believe their plan is unfolding exactly as planned and that revenues will begin to spike well before the end of this year. Patient and confident investors will be rewarded big.

    This is a rare buying opportunity giving buyers a second chance while shares are still cheap.

    Read the recent article that was a very well thought out analysis of MHCC. The projections call for a $15 stock in 18 months and that is based on very conservative projections.

    Sentiment: Strong Buy

  • Reply to

    Billwilliams

    by skb37_4 Aug 20, 2014 5:05 PM
    racavalli racavalli Aug 20, 2014 6:48 PM Flag

    If this is your first investment you are about to get spoiled for life.

    Sentiment: Strong Buy

  • Reply to

    Pure Buy Now

    by neurogesxstockmanipulation Aug 8, 2014 1:52 PM
    racavalli racavalli Aug 20, 2014 11:38 AM Flag

    I agree because management has been working with QSR's and it should be getting close to a time when major decisions will be made. We already know from previous restaurant testing that SDC works far better than anything else, so the only reasonable conclusion is that PURE will experience new orders that will grow substantially because the number of QSR's is expected to be large and that will be reflected in upcoming financial reporting. The only logical conclusion is that PURE is a very strong buy today.

    Sentiment: Strong Buy

  • racavalli racavalli Aug 19, 2014 5:10 PM Flag

    optina has extremely high value as well because it will serve many broad indications

    nce001 is a new class of cancer therapeutic the company is quietly developing

    ampion is big but they have many many more

    Sentiment: Strong Buy

  • racavalli racavalli Aug 19, 2014 4:54 PM Flag

    management does not own controlling interest and can not stop a buyout if the majority of shareholders approve.

    Problem is that most shareholders of AMPE are worn out from seeing excessive undervaluations and will likely tumble easily.

    Sentiment: Strong Buy

  • racavalli racavalli Aug 19, 2014 2:13 PM Flag

    Big Pharma would rather pay a higher price and remove as much risk as possible.

    BUT....

    Now that the factory to manufacture Ampion has been cleared and now that results for the FINAL trial for Ampion is within days of release, if results are as good as all previous trial results, it is more likely than not that Big Pharma may step up from out of the blue with a tender offer for the entire company. It especially makes sense since the valuation is so low and therefore attractive.

    May not happen, but if I had to bet, I would bet that Ampio is bought out sooner than later because it is such an outstanding value with very large potential for the buyer and big pharma needs acquisitions to offset the patent cliff..

    Sentiment: Strong Buy

ADUS
21.88-0.28(-1.26%)11:37 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.